Wall Street Weighs In on UnitedHealth Stock Amid Selloff
UnitedHealth Group's stock has tumbled 36% year-to-date despite a strong Q3 earnings beat, with Medicare Advantage cost concerns and a DOJ probe weighing on shares. Bernstein analyst Lance Wilkes sees opportunity in the dip, raising his price target to $440 and maintaining a Buy rating.
Margin recovery in MA and Medicaid businesses could fuel an earnings rebound, Wilkes argues, citing upcoming rate cuts and reduced competition. The stock's current valuation appears attractive given projected EPS growth through 2027.